OPEN LETTER TO THE UK GOVERNMENT
ZDENKO KOS DrVS MRCVS MSc MEc BScEcon(Hons) MBA • Oct 21, 2024
TRANSFORMATIONAL CANCER TREATMENT, Sir CHRIS HOY & UK Gov Approval
Mrs Rachel Reeves MP, Chancellor of Exchequer
Mr Jonathan Reynolds MP, Business Secretary
Mr Wes Streeting MP, Health Secretary
Mrs Lisa Nandy MP, Sport Secretary
Date: 21st October 2024
Dear Government officials
Re: Open Letter to the Government of United Kingdom
Transformational cancer treatment, Sir Chris Hoy and British Government approval
Since the announcement of Sir Chris Hoy’s terminal cancer, I have received in excess of 200 requests per day to help with my (our) medication/treatment. I recognise that Sir Chris, the six times Olympic Gold Winner, and his wife Sarra are in nearly every Brits heart; but all I can currently do is switch my phone off and pretend that I am not available.
You, as the government, have not been bothered to answer my and my solicitor’s recent letters. Therefore, I am currently unable to help Sir Chris Hoy and his wife Sarra, as well as thousands and thousands of cancer patients in the United Kingdom, as my hands are tied.
My (our) medications have been approved by the European Medical Association (EMA) but not by the British MHRA, which is the fault of Mr Boris Johnson all the subsequent Conservative Prime Ministers thereafter. The rest of the history you know.
I will not now be registering my medications for four (4) most common cancers in the United Kingdom as well not for the fifth - Prostate Cancer, because of all the bureaucratic issues and other issues which I have pointed out in my previous correspondence with Rachel Reeve, Jonathon Reynolds, Wes Streeting, Lisa Nandy and others.
We are in position to help the Hoys. However, to progress this our German pharmaceutical partner would need to co-ordinate everything and prepare all the necessary tablets/ cocktails/ infusions/ injections for administration either in a Swiss, German or Italian hospital.
My tablets/ cocktails/ infusions/ injections needs to be prepared, as you are already more than aware, based on the specific DNA - or for a group of similar DNAs - to have the proper effect on the patient(s).
So, as well as their consent, they would need to provide their DNA, weight, height, complete diagnose and dob data, etc, …
At the end of the day, for me the patients are always first and I would like to help at any time and any occasions whenever possible.
This, of course, include Sir Chris and his wife Sarra. As I stated, we can provide treatment in Germany or Switzerland or Italy, but not in the United Kingdom.
My children and I went through eleven distressing years supporting my wife’s battle with cancer. We realised she was being used as a guinea pig; on occasions she was given 17 different medications daily, including four which shouldn’t be used at the same time.
When I finally met with her GP, I was told that the medications were prescribed by three hospital consultants; each had prescribed different drugs.
When I made a written complaint, I didn’t receive a single answer from the hospital or from the Health Secretary.
My wife passed away in 2019 aged 46, after we were together for 28 years. I still can’t comprehend why she had to die so young. We started this research programme in 2011; it is a great regret to me that we didn’t start earlier as she might still be alive, or her life could have been prolonged.
As it stands, we now have the top medication for the five main cancers – brain, breast, colon/rectum, lung as well for the fifth - prostate cancer.
My wife’s death, my own cancers, the death of some of those close to me, and the death of a few doctors I knew – all from cancer - sparked me to go on this long journey.
I am willing to help anyone, anywhere as I know the pain and suffering endured by patients and their families.
However, as I said, in the United Kingdom my hands are tied because your Government are not interested.
Consequently, if the medications are not (pre)registered in the United Kingdom there can’t be any hospital trials, and they can’t then be used more generally in the UK.
As far as Sir Chris Hoy and his wife Sarra are concerned, they would need to join hospital trials in either Germany, Italy or Switzerland.
Based on their personal data, my (our) laboratory in Switzerland will suggest the type and strength of medication, together with the best treatment protocol.
Our German pharmaceutical partner, who has been manufacturing the medication for us for last 5 years, normally then requires 5-7 days in extreme cases they can prepare in the same day. For reference, it is this partner who wants to buy the European licence and all the patents from me.
You are aware that my medications are prepared, in layman’s terms, on the basis of repairing errors in the cellular DNA; proteins like FANC1 and FANCD2 are used along with another nine (9) which are not currently recognised and even less used in whichever combination with whatever cancer medication in the United Kingdom. With Sir Chris Hoy along with proteins there might be also use of seven (7) different hormones. Not seeing and having all the data of Sir Hoy illness I can only speculate what I will never ever when medications or treatments are concerned.
Treatment is a complex process and procedure where there is no place for cutting the corners or room for improvisation.
I have personally tested all my medications myself. In 1998 I was diagnosed with High Grade Non-Hodgkin’s Lymphoma Cancer; St Thomas’ hospital gave me 3-4 months to live. I have subsequently had another 4 cancers. By going through standard treatment along with my medications, I have tested double combined treatment to the limits.
I have also tested on myself various combinations of chemotherapy/my medications and radiotherapy/my medications.
To date, there are literally no side effects of any kind in respect of my (our) medications.
We have been working with doctors in Australia, United States, Germany, Italy, Switzerland, France and also in the United Kingdom. Our goal is, and always was, and always will be to serve patients and their families with proper medication and treatment for treating cancers and to go further and further with our research.
I would like to help Sir Chris Hoy and his family; I would also like to help the many thousands and thousands of individuals in the UK suffering with cancer. To do this, the Government needs to respond to our proposal before I give up and sell the patent to our current German Pharma partner.
Yours faithfully
Zdenko Kos MRCVS MSc MEc BScEcon(Hons) MBA
https://thekosfoundation.online/prostate-cancer-standard-treatment
https://thekosfoundation.online/prostate-cancer--darexanatan
PROSTATE CANCER DATA Period 2020 -2025
Hospital Trials and Treatment with our NEW medications & Innovative methods
Mortality in EU 2020-2025: 1,381,522; (EU hospitals Standard Treatment); Our Data: 1,419,292
Mortality in the UK 2019-2024: 209,504 (UK hospitals Standard Treatments); Our Data: 225,089
RESULT by OUR NEW METHODS (Used from 2014-2019) and by
OUR NEW INNOVATIVE METHODS (Used from 2020-2025+)
Testing Period 2020-2025; All Age Groups
Tested patients in UK, Switzerland, Germany and Italy: 349.662
Fully recovered: 38.9%
Recovered (No treatments needed in the next 2 years monitoring every 6 months): 32.8%
Partially Recovered (Further treatments needed as precaution after 3-6months passed): 16.4%
Unknown Recovery/ Non-recovery: 11.4%
Deaths in Total: 0.5% (Highest % in the group 46-66).
Topics used in our core research areas along with MCCD's:
01. Multiparametric MRI and PET-PSMA imaging potentially allow some men to avoid invasive biopsies.
02. Usage ctDNA and other biomarkers to detect prostate cancer earlier and more accurately.
03. Increased use of precision medicine, such as “olaparib”, to treat men with specific genetic mutations (e.g., BRCA mutations).
04. Research into 2Lutetium-177 PSMA (Pluvicto)2 to target metastatic castration-resistant prostate cancer.
05. Research with usage of high-dose rate brachytherapy and others to minimize side effects like incontinence and erectile dysfunction.
06. Usage innovative treatment with drugs like DAREXANATAN for combined treatment
07. Optimizing Hormone Therapy by testing standard drugs like abiraterone, enzalutamide, and darolutamide can maintain efficacy while reducing harsh side effects in smaller doses.
08. Androgen Receptor (AR) - Research into how tumours evolve to survive despite hormone therapy, with a focus on that target resistance mechanisms.
09. Monitoring strategies on blocking cancer spread to the bones and managing advanced, recurrent disease.
10. Germline Genetic Testing as there are patients (9%) with advanced disease have specific genetic variations.
The graph above showing recovery/non-recovery status on 349,662 patients randomly taken for hospital trials and treatment where we have in
Stage 1 just 10% patients, Stage II just 20%, Stage III 30% and in Stage IV staggering 40% patients while hospitals in EU & UK gave us details for the same number of patients (349,662) in Stage 1 40%, Stage II 30%, Stage 3 20% and in Stage IV only10%. That further means that we have our mortality rate with innovative treatment well above all expectation low, sadly still 1 patients passed away despite that we overtake 40% of 349,662 patients with Stage IV cancer, in meanwhile under the standard hospital treatment in EU & UK 48 patients past away, having in mind that they have in Stage IV just 10% patients while we have 40%.
| Number of patients of 349,662 | Cancer Stage I | Cancer Stage II | Cancer Stage III | Cancer Stage IV |
|---|---|---|---|---|
| By Standard treatment in EU & UK hospital | 139,864 | 104,898 | 69,932 | 34,968 |
| By Our New Medications | 34,968 | 69,932 | 104,898 | 139,864 |
| By Our Innovative treatment | 34,968 | 69,932 | 104,898 | 139,864 |
MORTALITY:
In the Europe 2019-2024 > 19.3% (Going Up)
In the United Kingdom 2019-2024 > 14.5% (Going Up)
With our NEW Innovative Treatmen and Medication in Europe & United Kingdom 2020-2025 less that 1% (Just 0.5%) mortality rate was recorded.
The % of "Unknown Recovery / Non-Recovery" went down to just 11.4% (2018/23 was 17.7%, and 2019/2024 was to 18.1% mainly in both periods at the same age group 32-44 which we believe has increased due to usage of control drugs or drugs, heavily drinking and smoking and other habits. This group is monitored separately for the third time.
There is an increase of mortality in Europe for 6.2% where the cancer go up with male patients nearly for the same percentage, while in the UK mortality went up by 1.9%, yet again not hundred percent accurate data as hospitals around Europe and United Kingdom "escape" registration of the death to "push" death patient to different group as of course of the death.
OUR RESEARCH and MORTALITY DATABASE 2020-2025
Cancer is one of the biggest health challenges worldwide. Since starting the research in 2011/12, the percentage of all deaths from cancer has risen from 9.6% in 2011 to 14.9% 10 years later; in the last 5 years this has risen again to where we now have 16.8% on top of the previous five years screening of all deaths recorded as cancer deaths.
Taking into consideration that in the period 2020-2025 the average European and the United Kingdom population was 762.7 million, an average 5,128,206 new cases were reported during the same period. This is an ASR of 282, and a cumulative risk of 31.28%.
Breast, Colorectum, and Lung cancers were the most common cancers across both sexes.
The male population in this period, some 271.4 million, recorded an average of 2,617,448 new cancer cases per year; an ASR of 327.5 per 100,000 and a cumulative risk of 34.6%.
The top 3 most common cancers among males were Prostate, Lung, and Colorectum cancer.
The female population in this period, some 291.3 million, recorded an average 2,494,488 new cancer cases per year; an ASR of 268.9 and a cumulative risk of 27.5%.
The top 3 most common cancers in females were Breast, Colorectum, and Lung cancer.
A significant point with cancer in the female population was switching lung cancer from 3rd place to 2nd place, with colorectum cancer dropped back from 2nd place to 3rd place.
Our mortality database is a collection of death registration data which includes cause of death information from member states; we use only the data which has been properly coded to the International Classification of Diseases (ICD).
What has also changed in recent years is the age of the death rate. This had declined over time in several countries due to life improvements, early diagnoses, medical advances, and a general reduction in risk factors like smoking and even drinking. However, there is a worrying emerging trend with rates of cancer in the population group aged up to 16.
This is rising well over expectations, especially in the United Kingdom, Spain, France and lately also in Italy.
IMPORTANT: If you are interested on details by countries, areas, hospitals we can provide all the details which include also data over 100 dedicated cancer institution in the OECI network alone along with 66 specialized cancer centres in the United Kingdom. The Royal Marsden NHS Foundation Trust still represent and forms Europe's biggest comprehensive cancer center along with The Christie NHS Foundation Trust. Our data include all cancer alliances around the Europe and United Kingdom. Through mappings we worked out that the Germany has much higher density of oncology facilities in comparison with the United Kingdom. The complete research and data are digital data for which the interested parties need a special authorisation code available on written request and one off payment.
Our research and data are collection of complete health
data covering nearly 562.7 million residents of Europe and Great Britain, includes data on individuals according to their non-cancerous
diseases, because we have also conducted a parallel review, screening an mapping of which types of patients with other diseases develop one of the cancers over time
(this is one off research - none similar exists).
